Chemical engineers could hold the key that helps pharmaceutical companies — facing pressure to control rising drug prices and competition from generics — reduce their manufacturing costs.
Disruptive technologies, such as disposable bioreactors, metabolic ?ux models, and glycoengineered yeast, could change the face — and pace — of biomanufacturing.
This analysis shows how to quantify the capital and operating differences between single-use and reusable equipment for a model biopharmaceutical process.
Automation can pay large dividends in the form of reduced process cycle times, lower operational costs, and more-consistent processes for manufacturing high-quality pharmaceutical products.